Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fisetin for Interstitial Lung Disease in CVID
NCT05593588Phase 2Active, not recruiting
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in common variable immunodeficiency (CVID) and interstitial lung disease (ILD) comparing Fisetin Group with Placebo Group (2 arms). Primary endpoint: Change in immunophenotyping of peripheral T lymphocytes at 6 months. Started Apr 2023; status: active, not recruiting.
02
Drugs
fisetin
03
Conditions
common variable immunodeficiency (CVID)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05593588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593588.